Serum 14-3-3? A Predictor Of Secondary Sjögren’s Syndrome In SLE

Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)?

With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. This may also lead to misdiagnoses of other connective tissue disorders.

New data on 14-3-3η (eta) enhances the detection rates of patients with secondary SS

• Serum 14-3-3η levels were found to be elevated in SLE patients with secondary SS compared to those with SLE without SS
• ROC analysis showed serum 14-3-3η levels as a predictor of SLE with secondary SS
• Levels of 14-3-3η significantly correlate with clinical and serological parameters (occular siccia, anti-LA and anti-Ro) in patients with secondary SS among SLE patients

Whether serum 14-3-3η levels are used alone in management of disease or in combination with other serological measurements, 14-3-3η clearly improves the diagnostic utility of patients with autoimmune conditions.

The 14-3-3η blood test is available in the U.S through LabCorp, Quest Diagnostics and RDL Reference Laboratory. In Canada, the test is available through Dynacare.